Deals
India’s Dr Reddy’s and China’s Bio-Thera have struck a deal covering ustekinumab and golimumab biosimilars in multiple markets in south-east Asia.
Cipla has bolstered its ophthalmology portfolio and increased its global offering after chalking up an agreement to add Formosa Pharmaceuticals’ USFDA-approved clobetasol propionate 0.05% ophthalmic suspension.
Along with financial backing from the Canadian government, a fresh, decade-long partnership with Sandoz Canada will allow Delpharm to carry out modernization plans for its manufacturing facility in Boucherville, securing the local supply chain for sterile injectable medicines.
Sweden’s Xbrane has struck a deal to transfer its R&D operations in Sweden and its Cimzia (certolizumab pegol) biosimilar candidate to Alvotech, in a transaction worth around $27m. However, Xbrane told Generics Bulletin that it was not getting out of biosimilar development altogether.
Fresenius Kabi has become the latest biosimilar sponsor to settle US litigation with Amgen over its Prolia/Xgeva rivals. The German firm revealed to Generics Bulletin details of launch dates for its denosumab in both the US and Europe.
Both vexed by bankruptcies and opioid litigation, Endo and Mallinckrodt will merge in a deal valued at $6.7bn. The new company will spin out its generics and sterile injectable business.
Biocon Biologics is partnering with Civica to supply insulin aspart drug substance that will be used for final US manufacturing by Civica at its plant in Petersburg, Virginia.
The same day as Samsung Bioepis and Sandoz launched their partnered Pyzchiva biosimilar rival to Stelara in the US, originator J&J hit the Korean developer with a lawsuit claiming that a private-label commercialization deal with a US pharmacy benefit manager violates the ustekinumab settlement that allowed the firms to launch.
A journey began eight years ago continues for Doc Generici – now rebranded as DOC Pharma – as it continues to diversify its offerings beyond conventional generic prescription pharmaceuticals.
Having secured approvals for the Eylea biosimilar in major markets such as the US and Europe, Formycon has signed a fresh licensing deal with Lotus Pharmaceutical, giving away rights to the asset in the APAC region.
Canada’s largest generics manufacturer Apotex will look to expand its channels to include health food stores, new professional channels including naturopathic doctors, and grocery retail channels, after acquiring Ontario-based natural health firm CanPrev for an undisclosed sum.
Having recently acquired Coherus’ biosimilar pegfilgrastim franchise in the US and welcomed FDA approval for its partnered ustekinumab biosimilar, Accord Biopharma is again spending big to flesh out its US biosimilar pipeline.
India’s Gland Pharma had much to discuss during its financial third-quarter earnings call, including a recent CDMO partnership with China’s Shanghai Henlius Biotech that could lead to the establishment of further manufacturing space to meet demand.
Fresh from filing its proposed biosimilar to Perjeta with the US FDA, Henlius has brought in Dr Reddy’s Laboratories as its US and European commercial partner for its proposed biosimilar to Darzalex, which has already succeeded in Phase I trials.
The Chinese company started the new year with a further business agreement after announcing a flurry of biosimilar partnership deals in 2024.
Egis is the beneficiary as Teva again trims its OTC portfolio with the sale of Hungarian skin-care brand Neogranormon.
Henlius casts a wider net for its biosimilars presence by locking in a fresh deal with the already-established partner Abbott. Also, the Chinese biosimilars developer has joined the Biosimilars Forum, securing its footing in the US.
A decade after Teva was slapped with a ten-figure fine for its alleged illegal activities blocking US generic competition to its Provigil brand, the Israeli firm has offloaded the narcolepsy drug and follow-up brand Nuvigil in the US to Apotex.
Teva has announced two major biosimilars deals in quick succession, partnering with Samsung Bioepis on its US Epysqli eculizumab rival to Soliris and Formycon on its European Ahzantive aflibercept challenger to Eylea.
Neuraxpharm’s business development team remains busy entering the new year, after signing yet another strategic deal – this time to grow the firm’s core presence in CNS disorder drugs.